FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm1, N.H. Eide1, K. Hveem2|3|4, N. Van Es5|6, V.M. Morelli1|7, S.K. Braekkan1|7, J.B. Hansen1|7 | 1Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; 2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 3HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Research, St. Olav University Hospital, Trondheim, Norway; 5Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 6Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; 7Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
496PDF: 111 -
OC05 | TIME TO START OF ANTICOAGULANT THERAPY AND SURVIVAL OUTCOMES IN CANCER PATIENTS WITH PULMONARY EMBOLISM K. Bria, B. Gage, M. Bealsey, K. Sanfilippo | Washington University in St. Louis School of Medicine, St. Louis, MO, USA
532PDF: 127 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
483PDF: 113 -
CO013 | INDICATIONS AND OUTCOMES OF OPTIONAL INFERIOR CAVA FILTERS IN CANCER-ASSOCIATED THROMBOSIS AND IN NON CANCER PATENTS WITH VENOUS THROMBOEMBOLISM B. Cosmi1|2, A. Cannizzaro2, M. Soldati2, L. Borgese2, S. Cavara1|2, M. Sartori2, L. Braccischi3, M. Taninokuchi Tomassoni4, D. Imberti5, V.O. Herasimchyj5, C. Mosconi3|4 | 1Angiology and Blood Coagulation Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; 4Department of Radiology, IRCCS Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy; 5Department of Medicine and Surgery, University of Parma, Italy; 6Haemostasis and Thrombosis Center, Internal Medicine Department, Ospedale di Piacenza, Italy
171PDF: 32 -
Platelet distribution width is associated with cardiovascular mortality in an adult general population
3109PDF: 530Supplementary Material: 148 -
PO001 | EMERGENCY DEPARTMENT MANAGEMENT OF PULMONARY EMBOLISM IN CANCER PATIENTS: PROGNOSTIC STRATIFICATION AND OUTCOMES A. Decursu1, L. Galli2, LM. Caiano2, S. Bozzato2, E. Ruggeri1, F. Paletta3, L. Vulcano1, L. Bertù1, F. Cortellaro2, W. Ageno4, MP. Donadini1|2 | 1Università degli studi dell'Insubria, Italy; 2ASST Sette Laghi, Italy; 3Università degli studi di Milano-Bicocca, Italy; 4Università degli studi di Padova, Italy
61PDF: 32 -
The key to fibrinolysis and thrombolysis
1721PDF: 542HTML: 273 -
CO018 | THE MOLI-SANI RISK SCORE, A MEASURE OF MODIFIABLE CARDIOVASCULAR RISK, PREDICTS NON-CARDIOVASCULAR MORTALITY AND SELECTED CANCERS, BUT NOT NEURODEGENERATIVE DISEASES F. Bracone1, S. Costanzo1|2, M. Bonaccio1, T. Panzera1, A. De Curtis1, S. Magnacca1, C. Cerletti1, MB. Donati1, G. de Gaetano1, L. Iacoviello1|3, A. Di Castelnuovo1 | 1Unità di Ricerca di Epidemiologia e Prevenzione, IRCCS Neuromed, Pozzilli, Italy; 2Università della Insubria, Varese, Italy; 3Università LUM Giuseppe Degennaro, Casamassima, Italy
110PDF: 35 -
CO017 | LIFE'S SIMPLE 7 FOR CARDIOVASCULAR HEALTH IS ASSOCIATED WITH LOWER CANCER RISK IN THE MOLI-SANI STUDY M. Bonaccio1, A. Di Castelnuovo1, S. Costanzo1|2, CF. Martinez1, T. Panzera1, A. De Curtis1, S. Magnacca1, C. Cerletti1, MB. Donati1, G. de Gaetano1, L. Iacoviello1|3 | 1Research Unit of Epidemiology and Prevention, IRCCS NEUROMED, Pozzilli (IS), Italy; 2Dep. of Medicine and Surgery, University of Insubria, Varese, Italy; 3Dep. of Medicine and Surgery LUM University, Casamassima (BA), Italy
79PDF: 34 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
498PDF: 117 -
CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY L. Girardi1|2, W. Ageno3, L. Bertù1, C. Lodigiani4, L.A. Ciuffini4, M.C. Vedovati5, C. Becattini5, A. Sammarco6, G. Camporese6, G. Cuni1|7, C. Ambaglio7, M.P. Donadini1 | 1Research Center on Thromboembolic Diseases and Antithrombotic Treatment, Department of Medicine and Surgery, University of Insubria, Varese, Italy; 2Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada; 3Department of Medicine, University of Padua, Padova, Italy; 4Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 5Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy; 6Clinica Medica 1, Department of Medicine, DIMED, Padova University Hospital, Padova, Italy; 7Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
162PDF: 37 -
Anticoagulation in obese patients: challenges and strategies
2056PDF: 550HTML: 318XML: 203 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
549PDF: 118 -
PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS E. Marrone1, C. Arturo2, F. Cannavacciulo3, D. D’Ambrosio4, F. Gallucci1, M. Amitrano3, C. Di Gennaro2, P. Morella1, A. Maffettone5 | 1UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; 2UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; 3UOC Medicina Interna, AO Moscati, Avellino, Italy; 4UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; 5UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy
60PDF: 33 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
513PDF: 128 -
PO003 | CATHETER-RELATED THROMBOSIS IN CANCER PATIENTS: A RETROSPECTIVE REAL-WORLD STUDY G. Autiero1|3, S.A. Malerba1|2|4, F. Busato1|2, D. Tolomio1|2, M. Dalla Vestra1|2, F. Presotto1|2 | 1U.O. Medicina Generale, Osp. Dell'Angelo, Venezia-Mestre, Italy; 2U.O. Angiologia, Osp. Dell'Angelo, Venezia-Mestre, Italy; 3Dip. Medicina Interna, Università degli Studi di Padova, Italy; 4U.O.C. Medicina Generale ad indirizzo trombotico ed emorragico, Università degli studi di Padova, Italy
59PDF: 31 -
PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE S. Gilani, H. Rubbani, A. Mackie | Cancer Centre, University Hospitals of North Midlands, Staffordshire, UK
540PDF: 118 -
PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT S. Kozhukhov, N. Dovganych | SI “NSC “The M. D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 2Cardio-Oncology Center, Kyiv, Ukraine
521PDF: 121 -
CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas1,2, M. Marchetti1,3, L. Russo1, C.J. Tartari1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca5, A. Falanga1,3 All on behalf of the Hypercan Investigators | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; 3School of Medicine and Surgery, University of Milan Bicocca, Italy; 4University Vita-Salute San Raffaele, Milan, Italy; 5Fondazione ARTET Onlus, Bergamo, Italy
655PDF: 28 -
PO105 | IMPACT OF ECOG PERFORMANCE STATUS ON CANCER-ASSOCIATED THROMBOSIS TREATED WITH DOACS: DATA FROM A MULTICENTER COHORT STUDY R. Talerico1, F. Mancinetti1, C. Sacco2, M. Mazzetti3, E. Campello4, S. Birocchi5, S. Beccatini6, A. Porfidia1, C. Lodigiani2, P. Simioni4, G.M. Podda5, I. Mastandrea2, C. Becattini6, R. Pola1, M.C. Vedovati6 | 1Thrombosis Unit, Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Thrombosis and Hemorrhagic Diseases Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Interdisciplinary Internal Medicine, Careggi University Hospital, Firenze, Italy; 4First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 5Medicine II Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milano, Milano, Italy; 6Internal, Vascular and Emergency Medicine– Stroke Unit, University of Perugia, Perugia, Italy
62PDF: 32 -
PO35 | A MULTICENTRE AUDIT OF CURRENT TUMOUR THROMBOSIS MANAGEMENT IN THE UNITED KINGDOM A.A. Bhatti1, L. Tafesh1, A. Waton1, M. Thomas3, N. Prasannan3, A. Bhide3, R. Walsh3, T. Lucas3, K. White4, T. Bariana4, O. Tsiamita4, S. Soman4, P. Woolley5, I. Lacej5, K. Musgrave1|2 | 1Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 2Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 3University College London Hospitals NHS Foundation Trust, London, UK; 4Barts Health NHS Trust, London, UK; 5Imperial College Healthcare NHS Trust, London, UK
495PDF: 107 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
462PDF: 102 -
PO094 | ARTIFICIAL INTELLIGENCE IN PULMONARY EMBOLISM PHENOTYPING: A SCOPING REVIEW D. Santagata1, A. Abenante1, S. Cosci2, D. Steiner3, S. Nopp3, A. Squizzato1, M.P. Donadini1, F. Dentali1, C. Ay3, W. Ageno4 | 1Department of Medicine and Surgery, University of Insubria, Varese and Como, Italy; 2Department of Internal Medicine, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; 3Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; 4Department of Medicine, University of Padova, Padova, Italy
67PDF: 30 -
CO03 | Early discharge and home treatment of low-risk pulmonary embolism: a cohort study E. Ruggeri1, L. Vulcano1, W. Ageno2, F. Cortellaro3, M.P. Donadini3,4 | 1Scuola di Medicina, Università degli Studi dell’Insubria, Varese; 2Dipartimento di Medicina, Università degli Studi di Padova; 3Pronto Soccorso e Medicina d’Urgenza, Ospedale di Circolo, ASST Sette Laghi, Varese; 4Dipartimento di Medicina e Chirurgia, Università degli Studi dell’Insubria, Varese, Italy
689PDF: 36 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1474PDF: 325HTML: 215Supplementary: 107 -
CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY M. Marchetti1|2, T. Zollner1|2, O.C. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Torino, Italy; 7Department of Medicine, University of Padua, Padova, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Roma, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
164PDF: 32 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
531PDF: 106 -
CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis G. Gagliardi, E. Campello, A. Napolitano, B. Stocco, C. Di Gesù, G. Gobbo, I. Condonato, M. Allegra, G. Camporese, P. Scarinzi, R. Pesavento, F. Bilora, C. Bulato, A. Benetti, C. Samà, C. Portinari, G. Antonello, C. Goffi, L. Di Daniel, A. Zambon, L. Fabris, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
843PDF: 30 -
PO161 | A REGIONAL DIGITAL NETWORK FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A: A MODEL FOR INTEGRATED CARE M. Mattana1, S. Raso1, R. Tomasello1, MF. Mansueto1, C. Cammarata2, S. Siragusa3, M. Napolitano1|3 | 1A.O.O.R. Villa Sofia Cervello P.O. Cervello-UOC di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Italy; 2PO Sant'Elia, Caltanissetta, Italy; 3Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza (ProMISE), Università degli Studi di Palermo, Italy
54PDF: 29 -
CO-71 | ACQUIRED FACTOR XIII DEFICIENCY IN A PATIENT POST-CAR-T THERAPY FOR NON-HODGKIN LYMPHOMA: A CASE REPORT A. Strangio, M. Leotta, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
67PDF: 39 -
PO113 | A STRANGE CASE OF RECURRENT ISOLATED DIGITAL ARTERIAL THROMBOSIS M.M. Poggi, D. Bruni | SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy
67PDF: 42
1 - 47 of 47 items
